Drugs / PulmoBind
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02216279 | Sep 2014 → Sep 2015 | pulmonary hypertension | Montreal Heart Institute | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PulmoBind | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02216279 ↗ |
| Modality | Peptide | “PulmoBind is a peptide derived from human adrenomedullin (hAM1-52)” NCT02216279 ↗ |